-
1Academic Journal
Πηγή: Репродуктивное здоровье. Восточная Европа. :185-197
Θεματικοί όροι: оverall survival, predictive factors, advanced ovarian cancer, номограмма, postoperative сomplications, послеоперационные осложнения, 3. Good health, первичная циторедукция, nomogram, 03 medical and health sciences, 0302 clinical medicine, интервальная циторедукция, interval debulking surgery, факторы прогноза, распространенный рак яичников, primary debulking surgery
-
2Academic Journal
Συγγραφείς: A. S. Tjulandina, A. A. Rumyantsev, K. Y. Morkhov, V. M. Nechushkina, S. A. Tjulandin, А. С. Тюляндина, А. А. Румянцев, К. Ю. Морхов, В. М. Нечушкина, С. А. Тюляндин
Πηγή: Malignant tumours; Том 8, № 3 (2018); 86-94 ; Злокачественные опухоли; Том 8, № 3 (2018); 86-94 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: интервальная циторедукция, complete debulking, optimal cytoreduction, neoadjuvant chemotherapy, inter val debulking, полная циторедукция, оптимальная циторедукция, предоперационная химиотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/566/402; Румянцев А. А., Тюляндина А. С., Покатаев И. А., Тюляндин С. А. Спорные вопросы оптимальной тактики хирургического лечения больных распространенным раком яичников. Злокачественные опухоли. 2017. Т. 7. № 3 С. 13–22.; Румянцев А. А., Тюляндина А. С., Покатаев И. А., Купчан Д. З., Тюляндин С. А. Критерии отбора больных с высоким шансом достижения оптимальной и полной циторедукции. Злокачественные опухоли. 2017. Т. 7. № 4. С. 53–62.; Румянцев А. А., Тюляндина А. С., Покатаев И. А., Тюляндин С. А. Вопросы качества хирургического лечения при раке яичников. Злокачественные опухоли. 2018. Т. 8. № 1. С. 31–37.; Vergote I., Trope C. G., Amant F., Kristensen G. B., Ehlen T., Johnson N. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 2010. Vol. 363. P. 943–953.; Kehoe S., Hook J., Nankivell M., Jayson G. C., Kitchener H., Lopes T. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015. Vol. 386. P. 249–257.; Takashi O., Toyomi S., Toshaiki S., Toru N., Kazuhiro T., Kenichi M. et al. Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III / IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. J. Clin. Oncol. 2018. Vol. 36. (Suppl.; abstr. 5500).; Chi D. S., Musa F., Dao F., Zivanovic O., Sonoda Y., Leitao M. M. et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol. Oncol. 2012. Vol. 124 (1). P. 10–14.; Tanner E. J., Long K. C., Feffer J. B., Leitao M. M. Jr, Abu-Rustum N. R., Barakat R. R. et al. Parenchymal splenic etastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. Gynecol. Oncol. 2013. Vol. 128 (1). P. 28–33.; du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials. Cancer. 2009. Vol. 115 (6). P. 1234–1244.; Oza A. M., Cook A. D., Pfisterer J., Embleton A., Ledermann J. A., Pujade-Lauraine E. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015. Vol. 16 (8). P. 928–936.; https://www.malignanttumors.org/jour/article/view/566
-
3Academic Journal
Συγγραφείς: A. A. Rumyantsev, A. S. Tjulandina, I. A. Pokataev, D. Z. Kupchan, S. A. Tjulandin, А. А. Румянцев, А. С. Тюляндина, И. А. Покатаев, Д. З. Купчан, С. А. Тюляндин
Πηγή: Malignant tumours; Том 7, № 4 (2017); 53-62 ; Злокачественные опухоли; Том 7, № 4 (2017); 53-62 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: критерии отбора, interval debulking, primary debulking, neoadjuvant chemotherapy, patient selection, первичная циторедукция, интервальная циторедукция, неоадъювантная химиотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/439/350; Chang S. J., Hodeib M., Chang J., Bristow R. E. Survival impact of complete cytoreduction to no gross residual disease for advancedstage ovarian cancer: a meta-analysis. Gynecol Oncol., 2013 Sep, Vol. 130 (3), pp. 493–498.; du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials, Cancer, 2009, Vol. 115 (6), pp. 1234–44.; Melamed A., Hinchcliff E.M., Clemmer J. T., Bregar A. J., Uppal S., Bostock I. et al. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. Gynecol. Oncol., 2016 Nov, Vol. 143 (2), pp. 236–240.; Narod S., Sopik V. Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted? Gynecol. Oncol., 2017 Feb, Vol. 144 (2), pp. 238–240.; Тюляндин С. А., Деньгина Н. В., Коломиец Л. А., Морхов К. Ю., Нечушкина В.М., Покатаев И. А. и др. Практические рекомендации по лекарственному лечению рака яичников/первичного рака брюшины/рака маточных труб. Злокачественные опухоли. 2016. № 4. Спецвыпуск 2. С. 123–134. [Tjulandin S. A., Dengina N. V., Kolomiets L. A., Morkhov K. Yu., Nechushkina V.M., Pokataev I. A. et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu raka yaichnikov/pervichnogo raka bryushiny/raka matochnykh trub, Zlokachestvennye opukholi, 2016, No. 4, Special issue 2, pp. 123–134 (In Russ.)].; Ассоциация Онкологов России. Клинические рекомендации по диагностике и лечению больных раком яичников, маточной трубы или первичным раком брюшины. Москва, 2014. [Assotsiatsiya Onkologov Rossii. Klinicheskie rekomendatsii po diagnostike i lecheniyu bolnykh rakom yaichnikov, matochnoy truby ili pervichnym rakom bryushiny, Moscow, 2014 (In Russ.)].; Wright A.A., Bohlke K., Armstrong D.K., Bookman M.A., Cliby W.A., Coleman R. L. et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline, J. Clin. Oncol., 2016 Oct, Vol. 34 (28), pp. 3460–73.; NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1, 2017.; Kehoe S., Hook J., Nankivell M., Jayson G.C., Kitchener H., Lopes T. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet, 2015, Vol. 386, pp. 249–257.; Vergote I., Trope C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N. Engl. J. Med., 2010; Vol. 363, pp. 943–953.; Румянцев А.А., Тюляндина А.С., Покатаев И.А., Тюляндин С.А. Спорные вопросы оптимальной тактики хирургического лечения больных распространенным раком яичников. Злокачественные опухоли. 2017. Т. 7. № 3 С. 13-22. [Rumyantsev A.A., Tjulandina A.S., Pokataev I.A., Tjulandin S.A. Controversies in surgical treatment of advanced ovarian cancer, Malignant Tumours, Vol. 7, No. 3, pp. 13–22 (In Russ.)].; Vergote I., Coens C., Nankivell M., Kristensen G., Parmer M., Ehlen T. et al. Meta-analysis of the randomized EORTC and CHORUS Neoadjuvant versus Primary Debulking trials in advanced Ovarian Cancer, Oral presentation at 16th Biennial Meeting of the International Gynecologic Cancer Society.; Winter W. E. 3rd, Maxwell G. L., Tian C., Sundborg M. J., Rose G.S., Rose P.G. et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study, J. Clin. Oncol., 2008 Jan, Vol. 26 (1), pp. 83–89.; Chi D.S., Venkatraman E.S., Masson V., Hoskins W. J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma, Gynecol. Oncol., 2000 May, Vol. 77 (2), pp. 227–231.; Chi D.S., Zivanovic O., Palayekar M. J., Eisenhauer E. L., Abu-Rustum N.R., Sonoda Y. et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma, Gynecol. Oncol., 2009 Jan, Vol. 112 (1), pp. 6–10.; Nick A.M., Coleman R. L., Ramirez P. T., Sood A.K. A framework for a personalized surgical approach to ovarian cancer, Nat.Rev. Clin. Oncol., 2015 Apr, Vol. 12 (4), pp. 239–245.; Bristow R. E., Duska L.R., Lambrou N.C., Fishman E.K., O’Neill M. J. et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography, Cancer, 2000 Oct, Vol. 89 (7), pp. 1532–1540.; Kim H. J., Choi C.H., Lee Y.Y., Kim T. J., Lee J.W. et al. Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings, Taiwan J. Obstet. Gynecol., 2014 Sep, Vol. 53 (3), pp. 343–347.; Janco J.M., Glaser G., Kim B., McGree M. E., Weaver A. L. Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer, Gynecol. Oncol., 2015 Jul, Vol. 138 (1), pp. 70–77.; Dowdy S.C., Mullany S.A., Brandt K.R., Huppert B. J., Cliby W.A. et al. The Utility of Computed Tomography Scans in Predicting Suboptimal Cytoreductive Surgery in Women with Advanced Ovarian Carcinoma, Cancer, 2004 Jul, Vol. 101 (2), pp. 346–352.; Suidan R.S., Ramirez P. T., Sarasohn D.M., Teitcher J.B., Mironov S. et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer, Gynecol. Oncol., 2014 Sep, Vol. 134 (3), pp. 455–461.; Low R.N., Barone R.M., Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures, Ann. Surg. Oncol., 2015 May, Vol. 22 (5), pp. 1708–1715.; Kasper S.M., Dueholm M., Marinovskij E., Blaakaer J. Imaging diagnostics in ovarian cancer: magnetic resonance imaging and a scoring system guiding choice of primary treatment, Eur. J. Obstet. Gynecol. Reprod. Biol., 2016 Oct, Vol. 210, pp. 83–89.; Espada M., Garcia-Flores J.R., Jimenez M., Martinez-Vega V. Diffusion-weighted magnetic resonance imaging evaluation of intraabdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma, Eur. Radiol., 2013 Sep, Vol. 23 (9), pp. 2636–2642.; Shim S.H., Lee S. J., Kim S.O., Kim S.N., Kim D.Y., Lee J. J. et al. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients, Gynecol. Oncol., 2015 Jan, Vol. 136 (1), pp. 30–36.; Axtell A. E., Lee M.H., Bristow R. E., Dowdy S.C., Cliby W.A. et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer, J. Clin. Oncol., 2007 Feb, Vol. 25 (4), pp. 384–389.; Rutten M. J., van de Vrie R., Bruining A., Spijkerboer A.M., Mol B.W., Kenter G.G. et al. Predicting Surgical Outcome in Patients With International Federation of Gynecology and Obstetrics Stage III or IV Ovarian Cancer Using Computed Tomography, Int. J. Gynecol. Cancer, 2015 Mar, Vol. 25 (3), pp. 407–415.; Fagotti A., Ferrandina G., Fanfani F., Ercoli A., Lorusso D. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study, Ann. Surg. Oncol., 2006 Aug, Vol. 13 (8), pp. 1156–1161.; Fagotti A., Ferrandina G., Fanfani F., Garganese G., Vizzielli G. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma, Am. J. Obstet. Gynecol., 2008, Vol. 199 (6), 642. e1–6.; Rutten M. J., van Meurs H.S., van de Vrie R., Gaarenstroom K.N., Naaktgeboren C.A., van Gorp T. et al. Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial, J. Clin. Oncol., 2017 Feb, Vol. 35 (6), pp. 613–621.; Aletti G.D., Garbi A., Messori P., Achilarre M. T., Zanagnolo V., Rizzo S. et al. Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit, Gynecol. Oncol., 2017 Mar, Vol. 144 (3), pp. 468–473.; Fagotti A., Vizzielli G., Fanfani F., Costantini B., Ferrandina G., Galotta V. et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experience, Gynecol. Oncol., 2013 Nov, Vol. 131 (2), pp. 341–346.; Nick A.M., Coleman R. L., Ramirez K.M., Schmeler P. T., Soliman K.H., Burwaza J.K. et al. Personalized surgical therapy for advanced ovarian cancer. Presented at the American Society of Gynecologic Oncology Annual Meeting (2015).; Vergote I.B., van Nieuwenhuysen E., Vanderstichele A. How to Select Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients With Stage IIIC or IV Ovarian Carcinoma, J. Clin. Oncol., 2016 Sep 19, pii: JCO697458. [Epub ahead of print].; Querleu D., Planchamp F., Chiva L., Fotopoulou C., Barton D., Cibula D. et al. European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery, Int. J. Gynecol. Cancer, 2016 Sep, Vol. 26 (7), pp. 1354–1363.; https://www.malignanttumors.org/jour/article/view/439
-
4Academic Journal
Συγγραφείς: A. A. Rumyantsev, A. S. Tjulandina, I. A. Pokataev, S. A. Tjulandin, А. А. Румянцев, А С. Тюляндина, И. А. Покатаев, С. А. Тюляндин
Πηγή: Malignant tumours; № 3 (2017); 13-22 ; Злокачественные опухоли; № 3 (2017); 13-22 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: внутрибрюшинная химиотерапия, surgical treatment, primary debulking, interval debulking, chemotherapy, intraperitoneal chemotherapy, хирургическое лечение, первичная циторедукция, интервальная циторедукция, неоадъювантная химиотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/387/333; Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные заболевания в России в 2014 году (заболеваемость и смертность). М., 2016. 250 с. [Kaprin A. D., Starinskii V. V., Petrova G. V. Zlokachestvennye zabolevaniya v Rossii v 2014 godu (zabolevaemost’i smertnost’), Moscow, 2016, 250 p. (In Russ.)].; Howlader N., Noone A. M., Krapcho M. et al. SEER Cancer Statistics Review, 1975-2012, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.; Griffiths C. T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma, Natl. Cancer Inst. Monogr., 1975, Vol. 42, pp. 101–104.; Hoskins W. J. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol. Oncol., 1994, Vol. 55 (3 Pt. 2), pp. S91–S96.; Elattar A., Bryant A., Winter-Roach B. A., Hatem M., Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst. Rev., 2011, Issue 8, Art. No. CD007565.; Winter W. E. 3rd, Maxell G. L., Tian C., Carlson J. W., Ozols R. F., Rose P. G. et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study, J. Clin. Oncol., 2007, Vol. 25 (24), pp. 3621–3627.; du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials, Cancer, 2009, Vol. 115 (6), pp. 1234–1244.; Crawford S. C., Vasey P. A., Paul J., Hay A., Davis J. A., Kaye S. B. Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial, J. Clin. Oncol., 2005, Vol. 34; pp. 8802–8811.; Horowitz N. S., Miller A., Rungruang B., Richard S. D., Rodriguez N., Bookman M. A. et al. Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer: An Analysis of GOG 182, J. Clin. Oncol., 2015, Vol. 8, pp. 937–943.; Bookman M. A., Brady M. F., McGuire W. P., Harper P. G., Alberts D. S., Friedlander M. et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup, J. Clin. Oncol., 2009, Vol. 9, pp. 1419–1425.; Chi D. S., Eisenhauer E. L., Zivanovic O., Sonoda Y., Abu-Rustum N. R., Levine D. A. et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm, Gynecol. Oncol., 2009, Vol. 114 (1), pp. 26–31.; Harter P., Muallem Z. M., Buhrmann C., Lorenz D., Kaub C., Hils R. et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer, Gynecol. Oncol., 2011, Vol. 121 (3), pp. 615–619.; Vergote I., Trope C. G, Amant F., Kristensen G. B., Ehlen T., Johnson N. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N. Engl. J. Med., 2010, Vol. 363, pp. 943–953.; Vergote I., Trope C. G., Amant F., Kristensen G. B., Ehlen T., Johnson N. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N. Engl. J. Med., 2010, Vol. 363, pp. 943–953, Supplementary appendix.; Kehoe S., Hook J., Nankivell M., Jayson G. C., Kitchener H., Lopes T. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet, 2015, Vol. 386, pp. 249–257.; Kehoe S., Hook J., Nankivell M., Jayson G. C., Kitchener H., Lopes T. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet, 2015, Vol. 386, pp. 249–257, Supplementary appendix.; Chi D. S., Musa F., Dao F., Zivanovic O., Sonoda Y., Leitao M. M. et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT), Gynecol. Oncol., 2012, Vol. 124 (1), pp. 10–14.; Tanner E.J., Long K.C., Feffer J.B., Leitao M.M. Jr, Abu-Rustum N.R., Barakat R.R. et al. Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer, Gynecol. Oncol., 2013, Vol. 128 (1), pp. 28–33.; Pairetti M., Zanagnolo V., Aletti G. D., Bocciolone L., Colombo N., Landoni F. et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubalcancer: Surgical and oncological outcomes. Single institution experience, Gynecol. Oncol., 2010, Vol. 119 (2), pp. 259–264.; Oza A. M., Cook A. D., Pfisterer J., Embleton A., Ledermann J. A., Pujade-Lauraine E. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, Lancet Oncol., 2015, Vol. 16 (8), pp. 928–936.; van der Burg M. E., van Lent M., Buyse M., Kobierska A., Colombo N., Favall G. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer, N. Engl. J. Med., 1995, Vol. 332 (10), pp. 629–634.; Onda T., Satoh T., Saito T., Kasamatsu T., Nakanishi T., Nakamura K. et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III / IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602, Eur. J. Cancer, 2016, Vol. 64, pp. 22–31.; Luo Y., Lee M., Kim H. S., Chung H. H., Song Y. S. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer, Medicine (Baltimore), 2016, Vol. 95 (36), e4797.; Rauh-Hain J. A., Nitschmann C. C., Worley M. J. Jr, Bradford L. S., Berkowitz R. S., Schorge J. O. et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma, Gynecol. Oncol., 2013, Vol. 129 (1), pp. 63–68.; Melamed A., Hinchcliff E. M., Clemmer J. T., Bregar A. J., Uppal S., Bostock I. et al. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States, Gynecol. Oncol., 2016, Vol. 143 (2), pp. 236–240.; Meyer L. A., Sronin A. M., Sun C. C., Bixel K., Bookman M. A., Cristea M. C. et al. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer, J. Clin. Oncol., 2016, Vol. 32, pp. 3854–3863.; Narod S., Sopik V. Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted? Gynecol. Oncol., 2017, Vol. 144 (2), pp. 238–240.; Armstrong D. K., Bundy B., Wenzel L., Huang H. Q., Baergen R., Lele S. et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer, N. Engl. J. Med., 2006, Vol. 354, pp. 34–43.; Landrum L. M., Java J., Mathews C. A., Lanneau G. S. Jr, Copeland L. J., Armstrong D. K. et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study, Gynecol. Oncol., 2013, Vol. 130 (1), pp. 12–18.; Mueller J. J., Kelly A., Zhou Q., Iasonos A., Long Roche K., Sonoda Y. et al. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center, Gynecol. Oncol., 2016, Sep 28 [Epub ahead of print].; https://www.malignanttumors.org/jour/article/view/387